SIRPA and cancer: Activation of SIRPα initiates a signaling cascade that inhibits the phagocytic activity of macrophages, and CD47, therefore, functions as an anti‐phagocytic or “don't eat me” signal to avoid self‐elimination by phagocytes.[3] The administration of CD47‐blocking monoclonal antibodies for cancer treatment has been investigated in multiple clinical trials.[2]